The complete cardiovascular-focused cessation guide — 7 direct mechanisms of cardiac damage, the e-cigarette evidence, the risk recovery timeline after quitting, and cessation toolkit comparison with quit rates for each approach.
Smoking cessation has a cardiovascular benefit profile that no drug can match. Within one year of quitting, coronary artery disease risk falls by approximately 50%. Within 15 years, the cardiovascular risk of a former smoker is essentially equivalent to someone who never smoked.
This guide provides the cardiovascular-focused cessation education that most smokers never receive — the precise mechanisms of damage, the precise timeline of recovery, and a data-backed comparison of every cessation intervention available.
Endothelial dysfunction, accelerated atherosclerosis, thrombosis, CO toxicity, hypertension, arrhythmia, dyslipidemia — each explained precisely.
Why vaping is not a safe alternative — nicotine, formaldehyde, dual use, and the absence of long-term safety data.
Every cardiovascular benefit of cessation mapped to the week, month, and year it occurs.
Varenicline (33% quit rate), combination NRT (27%), bupropion (20%), patch alone (18%) — clinical trial data side by side.
1-800-QUIT-NOW, SmokefreeTXT, smokefree.gov — no prescription required to start.
Only 5-7% quit rate unassisted — the biology of nicotine addiction explained, and why that number is not a character flaw.
“Smoking cessation is the single highest-return cardiovascular intervention I can offer any patient. No medication, no procedure, no lifestyle change produces a 50% reduction in cardiac risk within one year. The data are extraordinary. The challenge is the addiction, and that is exactly where we meet you.”
The cardiovascular case for quitting — and every tool available to do it.
Get Smoking & Heart Guide — $37